|Pronunciation||flay vox' ate|
|Trade names||Urispas, others|
|Other names||Flavoxate hydrochloride|
|Main uses||Overactive bladder|
|Side effects||Dry mouth, decreased sweating, headache, blurry vision, constipation, urinary retention, sexual dysfunction, palpitations, agitation|
|Typical dose||100 to 200 mg TID or QID|
|Chemical and physical data|
|Molar mass||391.467 g·mol−1|
|3D model (JSmol)|
Flavoxate, sold under the brand name Urispas among others, is a medication used as to treat overactive bladder. It may also be used for the symptoms of a bladder infection. It is taken by mouth.
Common side effects include dry mouth, decreased sweating, headache, blurry vision, constipation, urinary retention, sexual dysfunction, palpitations, and agitation. While there is no evidence of harm in pregnancy, such use has not been well studied. It is an antispasmodic and anticholinergic which increases bladder capacity and decreases urinary frequency.
Flavoxate was approved for medical use in the United States in 1970. It is available as a generic medication. In the United Kingdom 90 tablets of 200 mg costs the NHS about £12 as of 2021. In the United States this amount costs about 48 USD.
Flavoxate is used to treat urinary bladder spasms.
Flavoxate is indicated for symptomatic relief of interstitial cystitis, dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.
It is used at a dose of 100 to 200 mg three or four times per day.
Flavoxate is generally well tolerated, but can potentially cause vomiting, upset stomach, dry mouth or throat, blurred vision, eye pain, and increased sensitivity of the eyes to light.
Flavoxate is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.
Society and culture
It is available under the trade name Urispas (Paladin)(india), Genurin (by Recordati, Italy) in Italy and KSA, Uritac by El Saad company in Syria, under the name Bladderon by Nippon Shinyaku of Japan, or Bladuril in Chile, Utispas ( Apex Pharma) in Nepal.
- "Flavoxate". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 6 May 2021. Retrieved 11 December 2021.
- "FlavoxATE Monograph for Professionals". Drugs.com. Archived from the original on 19 January 2021. Retrieved 11 December 2021.
- "DailyMed - FLAVOXATE HYDROCHLORIDE tablet". dailymed.nlm.nih.gov. Archived from the original on 14 July 2017. Retrieved 11 December 2021.
- "Flavoxate (Urispas) Use During Pregnancy". Drugs.com. Archived from the original on 28 October 2020. Retrieved 11 December 2021.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 822. ISBN 978-0857114105.
- "Flavoxate Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 11 December 2021.
- Mohammed ZS, Simi ZU, Tariq SM, Ali KR (November 2008). "Bilateral acute angle closure glaucoma in a 50 year old female after oral administration of flavoxate". British Journal of Clinical Pharmacology. 66 (5): 726–7. doi:10.1111/j.1365-2125.2008.03254.x. PMC 2661991. PMID 18754848.